CCN5 activation by free or encapsulated EGCG is required to render triple‐negative breast cancer cell viability and tumor progression

• Main Authors: Amlan Das (Author), Inamul Haque (Author), Priyanka Ray (Author), Arnab Ghosh (Author), Debasmita Dutta (Author), Mohiuddin Quadir (Author), Archana De (Author), Sumedha Gunewardena (Author), Indranil Chatterjee (Author), Snigdha Banerjee (Author), Scott Weir (Author), Sushanta K. Banerjee (Author)
• Format: Book
• Published: Wiley, 2021-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Epigallocatechin‐3‐gallate (EGCG) has been considered an anticancer agent despite conflicting and discrepant bioavailability views. EGCG impairs the viability and self‐renewal capacity of triple‐negative breast cancer (TNBC) cells and makes them sensitive to estrogen via activating ER‐α. Su...